Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Bigelovin
Cat. No.:
OB0225LY-0368
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Product Overview
Description:
Bigelovin is a selective retinoid X receptor α agonist.
Synonym:
3668-14-2; 6-O-acetylmexicanin; [(3aS,5R,5aR,8aR,9S,9aR)-5,8a-Dimethyl-1-methylidene-2,8-dioxo-3a,4,5,5a,9,9a-hexahydroazuleno[6,5-b]furan-9-yl] acetate; 6alpha,8alpha-Dihydroxy-4-oxo-ambrosa-2,11(13)-dien-12-oate-12,8-lactone acetate; 6alpha,8alpha-Dihydroxy-4-oxo-ambrosa-2,11(13)-dien-12-oic acid-12,8-lactone acetic acid
CAS No.:
3668-14-2
Compound CID:
3080597
Formula:
C17H20O5
Formula Weight:
304.34
Specification
Relative Density:
1.22 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Bigelovin can be used to modulate the mTOR pathway to induce apoptosis and autophagy.
Library Information
Targets:
Nuclear receptors; Reactive oxygen species
Receptors:
RAR/RXR; Reactive oxygen species; Retinoid X receptor α
Pathways:
Autophagy; NF-κB; Apoptosis; Immunology/Inflammation; Metabolism
Plate Number:
AOCL-5
Plate Location:
g3
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
60 mg/mL; 197.15 mM
